Immune reset: CAR-T therapy takes on lupus, myositis, and ITP

NCT ID NCT07174843

Recruiting now Disease control Sponsor: Shanghai Cell Therapy Group Co.,Ltd Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-phase study tests a new cell therapy called BZE2204 in 20 people with lupus, myositis, or immune thrombocytopenia (ITP) that has not responded to standard treatments. The therapy uses a patient's own immune cells, modified to target and calm the overactive immune system. The main goals are to check safety and see if it can reduce disease activity.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BZE2204 CAR-T cells (a type of immune cell therapy targeting CD19, CD22, and BCMA)
What this could lead to: If it works, this could point toward a way to control severe autoimmune diseases like lupus, myositis, or ITP without lifelong medication.
What could go wrong: This is a very early, small trial (20 people) focused on safety. CAR-T therapy can cause serious side effects like cytokine release syndrome, and it is not yet known if it will work for these conditions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IDIOPATHIC INFLAMMATORY MYOPATHIES(IIM) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acquired idiopathic inflammatory myopathy autoimmune disease myositis disease Purpura, Thrombocytopenic, Idiopathic systemic lupus erythematosus thrombocytopenia due to immune destruction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IDIOPATHIC INFLAMMATORY MYOPATHIES(IIM) IMMUNE THROMBOCYTOPENIA (ITP) SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)

Contacts and locations

Locations

Shanghai Mengchao Cancer Hospital
RECRUITING

Shanghai, Shanghai Municipality, 200240, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.